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Abstract
Background: Uridine has been advocated for the treatment of HIV-1/HAART-associated lipodystrophy (HALS), although its
metabolism in HIV-1-infected patients is poorly understood.
Methods: Plasma uridine concentrations were measured in 35 controls and 221 HIV-1-infected patients and fat uridine in 15
controls and 19 patients. The diagnosis of HALS was performed following the criteria of the Lipodystrophy Severity Grading
Scale. Uridine was measured by a binary gradient-elution HPLC method. Analysis of genes encoding uridine metabolizing
enzymes in fat was performed with TaqMan RT-PCR.
Results: Median plasma uridine concentrations for HIV-1-infected patients were 3.80 mmol/l (interquartile range: 1.60), and
for controls 4.60 mmol/l (IQR: 1.8) (P = 0.0009). In fat, they were of 6.0 (3.67), and 2.8 (4.65) nmol/mg of protein, respectively
(P = 0.0118). Patients with a mixed HALS form had a median plasma uridine level of 4.0 (IC95%: 3.40–4.80) whereas in those
with isolated lipoatrophy it was 3.25 (2.55–4.15) mmol/l/l (P = 0.0066). The expression of uridine cytidine kinase and uridine
phosphorylase genes was significantly decreased in all groups of patients with respect to controls. A higher expression of
the mRNAs for concentrative nucleoside transporters was found in HIV-1-infected patients with respect to healthy controls.
Conclusions: HIV-1 infection is associated with a decrease in plasma uridine and a shift of uridine to the adipose tissue
compartment. Antiretroviral therapy was not associated with plasma uridine concentrations, but pure lipoatrophic HALS
was associated with significantly lower plasma uridine concentrations.
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Introduction
Pyrimidines are synthesized de novo through a multistep process
starting from glutamine and carbon dioxide to form the
pyrimidine ring, orotic acid [1]. The synthesis of orotic acid is
catalyzed by dihydroorotate dehydrogenase (DHODH), an
enzyme located in the inner mitochondrial membrane, and
functional connection to the respiratory chain via ubiquinone
ensures efficient oxidation of dihydroorotate [2]. Then, orotate is
converted to its nucleotide form in the presence of 5-phosphor-
ylribose-pyrophosphate. Orotate monophosphate is converted by
a multifunctional enzyme, uridine monophosphate (UMP) syn-
thase to the nucleotide UMP (Figure 1). UMP is the pivotal
nucleotide from which uridine nucleotides di-and triphosphates
are formed by ATP-dependent kinases [3]. A large portion of the
pyrimidines are salvaged from the degradation of the nucleic acids
and nucleotides [4]. The concentration of circulating plasma
uridine is tightly regulated throughout different species and
individuals [5,6]. The liver appears to have this homeostatic
control on uridine degradation and formation [7]. Uridine is
essentially cleared in a single pass through the liver and is replaced
by ‘‘new uridine’’ formed by de novo synthesis [7].
Besides the critical role of uridine in the synthesis of RNA and
bio-membranes, there is a role for uridine in regulating a series of
biological functions such as complex effects in the regulation of
vascular resistance, a role in spermatogenesis, a modulatory effect
on the peripheral nervous system, and maintenance of normal
CNS activity [8]. In animal models, uridine reduces anxiety, is a
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sleep-inducing factor, and may regulate body temperature [8].
Aside from its physiological effects, uridine appears to have
remarkable functions in tissues under stress or pathological
situations such as restoration of myocardial ATP concentrations
[9], maintenance of brain metabolism during ischemia or severe
hypoglycemia [10], recovery from neuronal degeneration pro-
duced by diabetic neuropathy [11], and as a rescue agent in 5-
fluorouracil therapy to decrease bone marrow and gastrointestinal
toxicity [12].
The triphosphates are the active forms of the nucleoside
analogue reverse transcriptase inhibitors, but they also inhibit
polymerase gamma, resulting in mitochondrial DNA depletion
[13], although reduction of mitochondrial DNA copy number is
also associated to HIV infection in itself [14]. Because the de
novo pyrimidine synthesis needs the correct function of the
mitochondrial respiratory chain, pyrimidine nucleotide depletion
has been hypothesized to contribute to this toxicity by
exacerbating the competitive effect of the analogues [15].
However, the effect of these drugs on patients’ uridine
concentrations has been studied in few cases [16]. Uridine has
been able to abrogate the adverse effects of antiretroviral
pyrimidine analogues in adipocytes [17], and the benefitial
effects of uridine supplementation in cell culture models of
stavudine toxicity seems to involve the recovery from nucleoside
analogue-induced pyrimidine depletion, because uridine supple-
mentation also prevented the effects of redoxal, a specific
DHODH inhibitor which, in turn, exacerbated the mitochon-
drial toxicity of the stavudine [15]. In a clinical trial,
supplementation of uridine to patients on thymidine analogues
was associated with fat recovery in limbs [18].
Our working hypothesis was that variations in plasma and fat
concentrations of uridine may be involved in the modulation of the
toxic effects of thymidine analogues. Specifically, we postulated
that the toxic effects of thymidine analogues might result in
pyrimidine depletion, detectable as a reduction of systemic and/or
fat uridine concentrations. Therefore, the aim of the present study
was to look for a relationship between plasma and fat uridine
concentrations and HIV-1/highly active antiretroviral (HAART)-
associated lipodystrophy syndrome (HALS).
Materials and Methods
Subjects
All patients were recruited through the same clinic at the
Hospital de la Santa Creu I Sant Pau, which attends a population of
1455 HIV-1-infected patients on active follow-up, and were
consecutive patients with an established diagnosis of HIV-1
infection. Patients were eligible whether or not they had HALS,
whether or not they were on antiretroviral therapy, and if they
were not taking uridine or derivatives. Subjects who were
hospitalized or had a frank cognitive impairment such as delirium
or dementia on enrolment were not eligible. Patients with
opportunistic infections, acute hepatitis, liver insufficiency, neo-
plasms or fever of undetermined origin were excluded from the
study. At the time of study entry no patient used any other drug
known to influence glucose metabolism or fat distribution.
Informed consent was obtained from the patients at study entry.
The diagnosis of AIDS was based on the 1993 revised case
definition of the Centers for Disease Control and Prevention
(CDC) [19]. Controls were recruited among Hospital personnel
and had to be negative for HIV-1 infection and be between 35 and
45 years of age with a proportion of males of about 70%. To be
eligible they did not have to meet any of the exclusion criteria.
Written informed consent was obtained from patients and controls
at study entry. The study was approved by the Ethics Committee
of the Hospital de la Santa Creu i Sant Pau.
Body composition measurements, definitions of HALS
and metabolic syndrome, and biochemistry laboratory
measurements
Body composition measurements, definitions of HALS and
metabolic syndrome have been described elsewhere [20]. All
laboratory investigations were performed as previously described
[21]. All laboratory samples, including those for uridine determi-
Figure 1. Schematic representation of uridine synthesis and its transport into the cell. MP = monophosphate.
doi:10.1371/journal.pone.0013896.g001
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nation, were obtained after a 12 hr overnight fasting. (Supporting
information file S1).
Fat tissue samples
These were obtained from subcutaneous adipose tissue (SAT)
depots through a small surgical biopsy performed by an 8 mm
punch under local anesthesia with mepivacaine. One half of the
SAT obtained was immediately frozen in liquid nitrogen and
stored at 280uC until RNA extraction (see below). The remaining
was used in fresh for determining fat uridine concentrations.
Measurement of plasma and fat uridine concentrations
For uridine determination, anticoagulated blood was centri-
fuged at 1,5006 g and plasma was separated and kept at 220 C
until analysis. Fat tissue was homogenated in the presence of 10
volumes (e.g., 50 mg of tissue +500 ml) of homogenization buffer
(10 mmol/l HEPES pH 7.5; 5 mmol/l EDTA; 5 mmol/l DTT;
5 mmol/l MgCl2; plus Complete-Mini
TM protease inhibitor cocktail,
Roche), in an ice-cold bath. After centrifugation, the supernatant
was saved and protein concentration was determined by the
Bradford method [22].
Uridine was measured by a binary gradient-elution HPLC
method. 200 ml of plasma or tissue homogenate were deprotein-
ized by the addition of 9 ml of cold perchloric acid 11.7 mol/l
(final concentration 0.5 mol/l) and kept 5 min on ice. Precipitated
proteins were eliminated by centrifugation and 5 ml of the
supernatant were injected into an Acquity UPLC apparatus
(Waters, Milford, MA) and eluted at 0.5 ml/min with a saline
buffer eluent A (20 mM ammonium acetate, pH 5.6) and an
organic eluent B (methanol gradient grade) according to the
following gradient: 0 to 1.1 min, 100% eluent A; 1.1 to 6.1 min,
100% to 82.6% eluent A; 6.1 to 6.2 min, 82.6 to 100% eluent A;
6.2 to 7.2 min, 100% eluent A. The column used was an Acquity
UPLC BEH C18 column 10062.1 mm, 130 A˚ pore size, 1.7 mm
particle size (Waters). Optical absorbance of the eluate was
monitored at 267 nm and definitive identification of the uridine
peak was based upon retention time and treatment of a second
aliquot of the sample with a large excess of purified E. coli
thymidine phosphorylase (Sigma-Aldrich, St. Louis, MO) to
eliminate enzymatically the uridine peak. The area from residual
peaks coeluting with uridine and still present after treatment with
E. coli thymidine phosphorylase was substracted from the area of
the uridine peak obtained in the untreated aliquot, to ensure no
overestimation of uridine concentration. The quantitation of the
nucleoside was based on peak areas using external aqueous
standards. The method had a between-day imprecision of 2.3%
(coefficient of variation) for a uridine concentration of 4.30 mmol/
l. Uridine concentrations in plasma of,3 to 5 mmol/l are found in
different species and individuals [5,6,12].
Expression of genes encoding uridine metabolism-
related enzymes and nucleoside transporters
RNA extraction was performed using a column-affinity based
methodology (Rneasy, Qiagen, Hilden. Germany). On-column
DNA digestion was performed during RNA purification (Rnase-
Free Dnase set, Qiagen). TaqMan Reverse Transcription and RT-
PCR reagents were used for mRNA analysis (Applied Biosystems,
Foster City, USA). One microgram RNA was transcribed into
cDNA random-hexamer primers and the real-time reverse
transcriptase-polymerase chain reaction was performed on the
ABI PRISM 7700HT sequence detection system (Applied
Biosystems). The TaqMan RT-PCR reaction was performed in
a final volume of 25 ml using TaqMan Universal PCR Master
Mix, NoAmpErase UNG reagent and the specific gene expression
primer probes. The TaqManGene Expression assays (Applied
Biosystems) used were: uridine-monophosphate synthase,
Hs00923516; uridine cytidine kinase-1, Hs00258815; uridine
phosphorylase, Hs00427695; uridine 59-monophosphate hydrolase
(also called cytosolic 59-nucleotidase III), Hs00826433; concentra-
tive nucleoside transport (CNT-1), Hs00984402; CNT-2,
Hs01035852; CNT-3, Hs00223220. Controls with no RNA,
primers, or reverse transcriptase were included in each set of
experiments. Each sample was run in duplicate and the amount of
the mRNA for the gene of interest in each sample was normalized
to that of the reference housekeeping control (HPRT1,
Hs999999009), as already reported [23] using the comparative
(2-DCT) method. Calculations based on a second, independent,
housekeeping gene (18S rRNA) led to similar results. Data are
expressed as means 6 SEM.
Measurement of plasma fatty acid concentrations
The serum composition of fatty acids was determined using the
method by Lepage and Roy [24]. Aliquots of 300 mL of plasma
were transferred into glass tubes for direct transesterification.
2 mL of methanol-benzene (4:1, v/v) with internal standard
(heptadecanoic acid, C17:0) and 0.01% butylhydroxytoluene, as
antioxidant. Samples were vortexed at low speed while slowly
adding 200 mL of acetyl chloride, little by little, over a period of 2
minutes. The tubes were tightly closed with teflon-lined caps and
vortexed 30 seconds.
Samples were then heated for 60 minutes at 100uC in a heating
block and shaking continuously at 600 rpm. After the tubes had
been cooled to room temperature, five millilitres of 6% (w/v)
potassium carbonate were then added. The samples were vortexed
for 30 seconds and centrifuged at 2500 rpm for 20 minutes at
15uC. The fatty acid methyl esters contained in the upper benzene
phase were transferred to gas chromatography vials and stored at
4uC until injection into the chromatograph.
The analysis was performed on a Varian CP-3900 gas
chromatograph equipped with a flame ionization detector, using
a capillary column model CP9205-VF-WAXms (Varian), 30 m
length 60.25 mm internal diameter 60.25 mm film thickness.
Individual fatty acids were identified by order of elution and upon
comparison with known commercially prepared fatty acid
standards (GLC 566-C, Nu-Chek Prep Inc.). Fatty acid methyl
ester peaks were identified by comparison of retention times of
standards and quantified in comparison to known commercially
prepared reference standards. The percentage of each fatty acid
class was expressed as percentage of total fatty acids.
Statistical analyses
All analyses were performed with the Statistical Package for
Social Sciences version 17.0 (SPSS, Chicago, IL). Data are
expressed as mean 6 SD or median with interquartile range
(IQR). Data that were not normally distributed, as determined
using the Kolmogorov-Smirnov test, were logarithmically trans-
formed before analysis. Student’s t test was used for comparison
between two groups, Pearson’s correlations or one-way ANOVA
and multiple testing were corrected using Bonferroni correction.
Stepwise logistic regression analysis was used to examine the
association of plasma uridine concentrations and other parameters
with HALS. The variables selected to enter into stepwise
regression were those that correlated significantly with plasma
uridine concentrations (after Bonferroni correction for multiple
testing). In all statistical tests, P values ,0.05 were considered
significant.
Uridine and HIV-1 Infection
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Results
Population studied
Two-hundred and twenty one HIV-1-infected patients and 35
healthy controls were studied. The demographics, HIV-1
infection, and antiretroviral exposure parameters from patients
and controls are shown in table 1. Mean duration of HIV-1
infection was 7.866.8 years (median: 7.0 [IQR: 12.2 years]), and
63 patients (28.5%) had had a prior AIDS-defining condition.
Fifty-nine patients were co-infected with hepatitis C virus (26.7%),
whereas 10 (4.5%) had chronic hepatitis B virus infection.
Anthropometric, metabolic data and plasma uridine concentra-
tions are shown in Table 2.
Antiretroviral drug exposure and immuno-virological
situation
Among treated patients, 59 (41.3%) had undetectable viral
load at the moment of the study. The other 84 treated patients
presented a median detectable viral load of 2.3 log10 copies/ml
(IQR: 1.1 log10 copies/ml). The mean CD4 count was 5896320
cells/mm3 (median: 531 [IQR. 425] cells/mm3). Nadir CD4 cell
count was ,100 cells/mm3 in 57 patients (25.8%). The
cumulated exposure to antiretroviral drugs is shown in table 1.
Twenty patients (13.9%) of the treated group were on an
antiretroviral regime that included AZT whereas 25 (17.5%) were
on a d4T-based regime at the moment plasma and fat uridine
concentrations were measured. There were not statistically
significant differences in plasma and fat uridine concentrations
between patients currently on AZT (P = 0.9930) or d4T
(P = 0.4944), either considered individually or as a combined
group (P = 0.5809).
Diagnosis of HALS and metabolic syndrome
HALS, based on 7 or more points on the Lipodystrophy Scale
Grading Score (LSGS), was diagnosed in 84 treated patients
(58.7%) whereas absence of HALS was found in 59 treated
patients (41.3%), and in all the naives. All 84 patients presented
with lipoatrophy, but in addition 44 (52.4%) had a mixed
lipoatrophic-lipohypertrophic form. Differences between HALS
and non-HALS patients are shown in tables 1 and 2. Patients with
a mixed form had a median plasma uridine level of 4.0 (IC95%:
3.40–4.80) whereas in those with isolated lipoatrophy it was 3.25
(2.55–4.15) mmol/l/l (P = 0.0066).
Plasma uridine concentrations and its correlation with
cardio-metabolic, HIV-1 infection and antiretroviral
therapy factors
Plasma uridine concentrations for HIV-1-infected patients
ranged from 1.60 to 7.4 mmol/l/l, with a mean value of
3.8561.18 mmol/l (median: 3.80; IQR: 1.60). The corresponding
values for controls were: range: 2.0–9.4 mmol/l, mean:
4.3661.28 mmol/l, median: 4.60, IQR: 1.80 mmol/l (P =
0.0009). Plasma uridine concentrations were not significantly
different between HALS and non-HALS patients (P = 0.3377).
Patients with plasma uridine concentrations ,3 mmol/l were
8.9% among controls, 16.7% among naı¨ves, 19.0% among
treated patients without HALS, and 29.6% among patients with
HALS (P = 0.0460). There was no sex difference in plasma
uridine concentrations for HIV-1-infected patients, but there
were statistically significant differences between controls (men:
median 5.0 [IQR: 1.5] vs. women: 3.45 [1.4], P = 0.0262). In
naı¨ve patients, there was a negative correlation between plasma
concentrations of uridine and viral load (R =20.2580,
P = 0.0228). Patients who were currently receiving treatment
with AZT or d4T had a median plasma uridine level of 3.90
[IQR: 1.67] whereas in those who did not it was 3.70 [IQR:
1.80) mmol/l (P = 0.4278). There was no correlation between
cumulated d4T use either in time (months) (R = 0.094,
P = 0.3935) or grams (R = 0.078, P = 0.4815). There were not
statistically significant differences between patients who did or did
not have AIDS, CD4 nadir ,100 cells/mm3, did or did not have
not clinical toxicity (peripheral neuropathy or pancreatitis),
HALS, HCV infection, and metabolic syndrome with respect
to plasma uridine concentrations. Lean subjects had median
plasma uridine concentrations of 3.7 [IQR: 1.5], overweight
subjects 4.1 [IQR: 1.8], and obese subjects 3.9 [IQR:
1.67] mmol/l (P = 0.0152 for lean vs. obese). The correlations of
plasma uridine concentrations with metabolic, infectious and
treatment factors are shown in table 3. Plasma uridine
concentrations were not found to be independently associated
either with the metabolic syndrome or with HALS in HIV-1-
infected patients.
Table 1. Demographics, HIV-1 infection and antiretroviral
exposure parameters.
Parameter
Controls
(n = 35) HIV-1-infected patients P value
Naı¨ve
(n = 78)
HALS-
(n = 59)
HALS+
(n = 84)
Age, mean
6 SD, (y)
43.765.0 36.9610.2 44.168.0 46.268.9 , 0.0001
Sex, men (%) 25 (71.4) 67 (85.9) 46 (77.9) 60 (71.4) 0.1302
Years of infection ---- 2.0 (1.0) 11.0 (10.0) 13.0 (6.0) , 0.0001
AIDS (%) ---- 3 (3.9) 18 (30.6 42 (50.0) , 0.0001
HCV infection (%) ---- 7 (9.5) 16 (27.6) 36 (42.9) , 0.0001
CD4 count/mm3 ---- 431 (302) 566 (416) 50 (463) 0.0136
Plasma viral load
(log10)
---- 4.3 (1.2) 1.8 (1.1) 1.7 (1.5) , 0.0001
Antiretroviral drug exposure
NRTI (m) ---- ---- 190.0 (106.0) 225.0 (83.0) 0.0069
NNRTI (m) ---- ---- 35.0 (52.7) 49.0 (48.5) 0.0519
PI (m) ---- ---- 43.0 (51.2) 49.0 (48.0 0.1114
AZT (m) ---- ---- 22.0 (71.0) 20.0 (47.7) 0.5533
AZT (g) ---- ---- 297.0 (852.0) 240.0 (824.5) 0.7448
d4T (m) ---- ---- 25.0 (61.2) 64.0 (37.5) , 0.0001
d4T (g) ---- ---- 62.4 (138.9) 144.9 (89.7) , 0.0001
3TC/FTC (m) ---- ---- 50.0 (77.0) 52.0 (65.5) 0.5220
ddI (m) ---- ---- 10.5 (33.5) 35.5 (61.5) 0.0028
ABC (m) ---- ---- 0(0) 0 (14.0) 0.8825
TDF (m) ---- ---- 10.0 (35.0) 8.0 (34.5) 0.6102
EFV (m) ---- ---- 0 (35.0) 2.5 (44.0) 0.2175
NVP (m) ---- ---- 0 (33.5) 6.0 (46.0) 0.1400
Parameters are expressed as median (interquartile range) unless specified. HCV,
hepatitis C virus, NRTI = nucleoside-analogue reverse transcriptase inhibitor,
NNRTI = non nucleoside-analogue reverse transcriptase inhibitor; PI =
protease inhibitor; AZT = zidovudine, d4T = stavudine, 3TC = lamivudine,
FTC = emtricitabine, ddI = didanosine, ABC = abacavir, TDF = tenofovir;
EFV = efavirenz, NVP = nevirapine, m = months; g = grams. HALS = HIV-1/
HAART-associated lipodystrophy syndrome.
doi:10.1371/journal.pone.0013896.t001
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Fat uridine concentrations
Uridine content was measured in fat biopsy samples from 19
patients (naı¨ve: 10, no HALS: 5, HALS: 4) and 15 controls.
Median uridine level in fat from HIV-1-infected patients was 6.0
[IQR: 3.67], and in controls, 2.8 [4.65] nmol/mg protein
(P = 0.0118). Median fat uridine level was 6.1 [0.50], 2.6 [1.85],
and 6.3 [3.4] nmol/mg protein, for naı¨ve, non-HALS patients,
and HALS patients, respectively (P = 0.3767). There was a
negative correlation between plasma and fat uridine concentra-
tions in HIV-1-infected patients (R =20.5210, P = 0.0223),
whereas such a correlation was not found for controls
(R = 0.0680, P = 0.8720). Median fat uridine level was 5.5 [IQR:
4.0] nmol/mg protein for those who were currently treated with
AZT or d4T, whereas it was 2.6 [IQR: 1.27] nmol/mg protein for
those not treated (P = 0.5369). There were no statistically
significant differences between patients with mixed HALS and
pure lipoatrophic HALS with respect to fat uridine concentrations
6.80 [IQR: 0] vs. 6.55 [IQR: 0.50] nmol/mg protein, respectively,
P = 0.4028). The only correlations were for EFV exposure
(R =20.4890, P = 0.0336), and for PUFAs level (R =20.5740,
P = 0.0252).
Expression of genes encoding uridine metabolism-
related enzymes and concentrative uridine transporters
The expression of genes involved in uridine metabolism is
depicted in figure 2. The expression of the transcript for UMP
synthase was not significantly modified in adipose tissue from all
HIV-1 infected patient groups with respect to controls, regardless
of having been treated or having developed HALS or not. The
expression of the gene for UMP hydrolase (also called cytosolic
59-nucleotidase III) was slightly decreased in naı¨ve patients but
unaltered in the other groups of HIV-infected patients (Figure 2).
The pattern of changes observed for uridine cytidine kinase and
uridine phosphorylase (UPase) indicated a significant decrease in
all groups of patients with respect to controls. There were no
changes in comparisons between naı¨ve and treated patients or in
patients with or without HALS. The expression of concentrative
nucleoside transporters (CNTs), potentially involved in concen-
trating intracellular uridine [25], showed a similar pattern of
changes in the three subtypes of transporters in naı¨ve and treated
patients, in agreement with previous findings [23]. Naı¨ve patients
showed a higher expression of the mRNAs for CNTs with respect
to healthy controls, which was statistically significant for CNT1
and CNT3. HAART-treated patients, either having HALS or
not, showed significantly higher concentrations of expression of
the three CNT mRNA subtypes with respect to controls and
naı¨ve, with distinct concentrations of statistical significance
depending on the CNT subtype (Figure 2). No differences were
observed for the expression of CNTs mRNAs between patients
with or without HALS.
Discussion
Our study does not suggest an association of the development of
features of HALS or metabolic syndrome with plasma and fat
concentrations of uridine, except for lipohypertrophy, but suggests
that HIV-1 infection is associated with a significant decrease in
uridine plasma concentrations. However, the number of patients
with uridine ,3 mmol/l was higher in patients with than in non-
HALS patients. Antiretroviral therapy that included thymidine
Table 2. Anthropometric, metabolic data and plasma uridine levels.
Parameter
Controls
(n = 35) HIV-1-infected patients P value
Naı¨ve
(n = 78)
HALS-
(n = 59)
HALS+
(n = 84)
BMI 24.4 (2.7) 23.6 (4,6) 23.8 (5.2) 23.5 (4.7) 0.1307
Waist circumference (cm) 89.0 (13.2) 86.0 (14.0) 88.0 (13.0) 86.5 (15.5) 0.0055
Waist-to-hip ratio 0.88 (0.09) 0.91 (0.11) 0.93 (0.09) 0.93 (0.11) , 0.0001
Total body fat (%) 24.8 (5.8) 21.5 (9.9) 22.5 (10,2) 19.7 (10.5) , 0.0001
Trunk/apendicular fat ratio 1.15 (0,5) 1.4 (1.2) 1.4 (1.1) 2.4 (1.2) , 0.0001
Total cholesterol (mmol/l) 5.2 (1.4) 4.7 (1.5) 4.9 (1.0) 4.8 (1.7) 0.0003
Triglycerides (mmol/l) 0.82 (0.43) 1.5 (1.4) 1.9 (1.3) 2.0 (1.7) , 0.0001
HDL cholesterol (mmol/l) 1.5 (0.5) 1.2 (0.5) 1.2 (0.5) 1.2 (0.4) , 0.0001
LDL cholesterol (mmol/l) 3.3 (1.3) 2.7 (1.2) 2.5 (1.0) 2.8 (1.0)) 0.0027
MUFAs (% with respect to total fatty acids) 23.9 (4.3) 26.3 (5.0) 27.9 (6.6) 28.3 (5.9) , 0.0001
PUFAs (% with respect to total fatty acids) 44.7 (4.0) 40.4 (5.5) 38.7 (7.3) 37.2 (7.6) , 0.0001
Glucose (mmol/l) 4.8 (0.6) 5.1 (0,9) 5.3 (0,7) 5.5. (1.1) , 0.0001
Insulin (pmol/l) 26.0 (33.2) 48.5 (63.5) 48.0 (54.2) 85.5 (61.5) , 0.0001
HOMA-IR 0.5 (0.7) 0.9 (1.1) 0.9 (1.0) 1.6 (1.2) , 0.0001
Systolic BP (mm Hg) 118.0 (17.7) 120 (16.5) 120 (20.0) 120 (20.0) 0.2649
Diastolic BP (mm Hg) 69.0 (15.0) 75.0 (10.0) 78 (12.0) 78 (10.0) 0.0081
Metabolic syndrome (%) 5 (14.3) 5 (6.4) 18 (30.5) 28 (33.3) , 0.0001
Uridine (mmol/l) 4.6 (1.8) 3.8 (1.3) 3.8 (1.6) 3.7 (1.7) 0.0034
Parameters are expressed as median (interquartile range) unless specified. P-values between individual groups are shown when ,0.05. BMI, body mass index; HDL, high
density lipoprotein; LDL, low density lipoprotein, HOMA-IR, homeostasis model assessment of insulin resistance; HALS = HIV-1/HAART-associated lipodystrophy
syndrome.
doi:10.1371/journal.pone.0013896.t002
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analogues did not influence uridine plasma concentrations. On the
other hand, fat uridine concentrations showed an inverse
correlation with plasma concentrations. This finding may be
explained by an over-expression of those genes that encode
concentrative nucleoside transporters, and particularly CNT3
[23,25], as well as by under-expression of genes encoding enzymes
leading to anabolic (UCK) or catabolic (UPase) uridine
consumption.
However, the present results have to be viewed in the light of
their inherent limitations. The first one comes from the nature of
the study; this is a cross-sectional study and therefore, no causal
relationships can or should be drawn. Second, for the majority of
patients, uridine was measured in plasma whereas the anatomical
and biological processes giving rise to HALS occur in the adipose
depots. We have some measurements of uridine in fat, and
although such measurements are highly reproducible and with
tight variability coefficients, their reliability is difficult to ascertain
[26]. In addition, the number of patients included in this substudy
was low, and this may hamper the validity of our results.
The plasma uridine results are trustworthy since we were
especially careful to avoid overestimations of the uridine peak, as
we have observed that some unknown compounds sometimes
coelute with uridine in our chromatographic separation. This fact
could explain, at least in part, the values slightly higher for uridine
plasma concentration reported by other groups [18], and could
account for the difference between our results, which do not detect
reduced uridine concentrations in treated patients, an the work by
Langmann et al that, in contrast, reports significat reductions in
dideoxy-NRTI treated patients [16]. We double tested enzymat-
ically the peak of uridine by treating a second aliquot of the
Table 3. Correlations of serum uridine levels with metabolic, infectious and treatment factors.
Serum uridine (mmol/l) Serum uridine (BMI-adjusted)
r P r P
BMI 0.1280 0.0465
Age 0.0140 0.8205 20.0040 0.9470
Waist circumference 0.0970 0.1218 0.0350 0.5890
WHR 20.0010 0.9868 20.0440 0.4920
Fat percentage 0.1630 0.0093 0.1250 0.0520
Trunk/apendicular fat ratio 2 0.0630 0.3126 -0.0690 0.2830
Fasting glucose 20.0820 0.1950 -0.0990 0.1260
Fasting insulin 0.0420 0.5092 20.0650 0.3170
HOMA-IR 20.0550 0.3785 20.0790 0.2200
MUFAs 20.2830 , 0.0001 -0.2900 , 0.0001
PUFAs 0.3130 , 0.0001 0.3220 , 0.0001
Total cholesterol 0.2010 0.0010 0.1700 0.0080
Triglycerides 20.0210 0.7434 20.0490 0.4490
LDL cholesterol 0.1950 0.0019 0.1650 0.0110
HDL cholesterol 0.1440 0.0217 0.1650 0.0100
VLDL cholesterol 20.0460 0.4703 20.0790 0.2260
Systolic BP 0.0370 0.5550 0.0370 0.5680
Diastolic BP 0.0020 0.9775 20.0050 0.9330
CD4 count 0.0200 0.7723 0.0150 0.8350
Plasma viral load (log10) 20.0120 0.8640 0.0050 0.9470
Years of infection 20.2230 0.0005 20.2130 0.0010
NRTI (m) 20.1670 0.0085 20.1710 0.0080
NNRTI (m) 20.0510 0.5506 20.0300 0.7330
PI (m) 20.1090 0.0864 20.1130 0.0800
AZT exposure (m) 20.0300 0.6352 20.0220 0.7340
AZT exposure (g) 20.0530 0.4058 20.0480 0.4620
d4T exposure (m) 20.1700 0.0074 20.1760 0.0070
d4T exposure (g) 20.1640 0.0097 20.1720 0.0080
ddI exposure (m) 20.1280 0.0437 20.1190 0.0670
EFV exposure (m) 20.1490 0.0182 20.1500 0.0200
NVP exposure (m) 20.0410 0.5164 20.0410 0.5320
BMI = body mass index, WHR = waist-to-hip ratio, HOMA-r, homeostasis model assessment of insulin resistance, MUFAs = monounsaturated fatty acids, PUFAs =
polyunsaturated fatty acids, LDL = low density lipoproteı´n, HDL = high density lipoproteı´n, VLDL = very low density lipoproteı´n, BP = blood pressure, NRTI =
nucleoside-analogue reverse transcriptase inhibitor, NNRTI = non nucleoside-analogue reverse transcriptase inhibitor; PI = protease inhibitor; AZT = zidovudine,
d4T = stavudine, ddI = didanosine, EFV = efavirenz, NVP = nevirapine, m = months; g = grams.
doi:10.1371/journal.pone.0013896.t003
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samples with an excess of thymidine phosphorylase from E. coli,
which ensures that we only measured true uridine, with no
interfering compounds eluting at the same retention time in the
chromatogram. This may explain why plasma uridine values
obtained in our patients with HALS are lower than those reported
by Sutinen et al. [18] for patients with clinically evident
lipoatrophy. On the other hand, the results obtained in our study
compared well with previously reported uridine plasma concen-
trations [5,6,12].
We have found that HIV-1 infection is associated with
significantly lower concentrations of uridine in plasma, whereas
there were not differences between HIV-1-infected patients
irrespective of their treatment status, but it was by the presence
of lipoatrophic HALS. This may be explained by the fact that,
unlike what happens in non-infected patients, there is a shift of
uridine towards adipose depots and maybe other tissues.
Additionally, among naı¨ve patients, a negative correlation was
found between uridine plasma concentrations and the amount of
plasma HIV-1 RNA. This may suggest its consumption during the
HIV-1 replicative cycle. On the other hand, alterations due to
HIV-1-infection in adipose tissue from patients, i.e. reduction in
the amounts of mitochondrial DNA [27], or impaired expression
of genes implicated in adipocyte anabolic functions [28], have
been previously reported.
Uridine supplementation has been advocated as a successful
treatment for thymidine analogues-related lipoatrophy based on a
short-term randomized, double-blind, placebo-controlled trial
[18]. However, recent data from a randomized, double blind,
placebo-controlled trial, failed to show any benefit of uridine
supplementation in terms of fat gain after 48 weeks of treatment
[29]. In addition, when compared with a strategy of switching
from thymidine analogues to tenofovir, supplementation with
uridine induced a pro-inflammatory state without showing benefit
in terms of fat gain [30]. Therefore, it seems that uridine
administration cannot reverse the adipose toxic effects of
thymidine analogues, and may even represent an additional risk
because of its potential inflammatory induction. This is not at odds
with our findings concerning the positive correlation between
Figure 2. Expression of genes encoding enzymes involved in uridine metabolism and concentrative nucleoside transporters (CNT).
Data from subcutaneous adipose tissue of uninfected controls and HIV-1 infected patients. Figure shows means + SEM for each specific
mRNA concentration (expressed as ratio relative to HPRT mRNA) from 6-8 patients/group. P values for statistical comparisons between groups are
shown when ,0.05. MP = monophosphate. HALS- = No HIV-1/HAART-associated lipodystrophy syndrome. HALS+ = HIV-1/HAART-associated
lipodystrophy syndrome. HAART = Highly Active AntiRetroviral Therapy.
doi:10.1371/journal.pone.0013896.g002
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plasma uridine concentrations and polyunsaturated fatty acid
(PUFAs) concentrations. The beneficial effects of PUFAs on the
cardiovascular system and on lipid profile are well known [31].
The concentrations of uridine in animal experimentation tissues
are usually far in excess of the concentration of uridine in plasma
[1]. Both, plasma and intracellular concentrations of uridine are
regulated by the catabolic activity of uridine phosphorylase
(UPase) and by transport mechanisms [9–11,32]. We have found
an underexpression of UPase in adipocytes which may partly
justify the greater concentration of fat uridine compared to that of
plasma (Figure 2). In addition, the increased expression of CNTs
in HIV-1-infected patients’ adipose tissue contribute to the shift of
uridine into the adipose cells. The overall shift in the expression of
these genes leading to induce an increase in the fat tissue
pyrimidine pool fits well with a previous report suggesting a role of
intracellular pyrimidine depletion associated to nucleoside ana-
logues toxicity [15]. Although we did not see any effects in the
systemic uridine concentrations, the increase of intracellular
uridine in treated patients might be, in fact, a reflex of a
compensatory mechanism to avoid intracellular pyrimidine
depletion.
In summary, our results suggest that uridine homeostasis is
profoundly disturbed by HIV-1 infection. Although plasma
concentrations in HIV-1-infected patients were lower than in
controls, the only additional uridine disturbance that could be
documented was unrelated to antiretroviral therapy but it was to
the development of pure lipoatrophic syndrome. These results are
in agreement with the lack of efficacy of uridine supplements in
HALS reversal as shown by ACTG 5229.
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